Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gw Pharmaceuticals plc
Headquarters: Cambridge, United Kingdom
Website: N/A
Year Founded: 1998
Status: Acquired
BioCentury | Mar 5, 2025
Deals
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz
Building in oncology, Jazz obtains targeted glioma therapy under FDA review
BioCentury | Oct 19, 2022
Deals
With biliary readout looming, Jazz-Zymeworks deal could grow much larger
Jazz pays $50M up front for rights to HER2-targeting bispecific, would owe more than 6x more to retain them after first pivotal readout
BioCentury | Jul 16, 2022
Management Tracks
Aurinia hires EVP of R&D, commercial head and VP of IR
Plus Enveda names Gilead’s Sekar as CBO and Covis hires a Poulin as SVP, general manager
BioCentury | Jun 29, 2022
Product Development
June 28 Quick Takes: Roivant, Pfizer create start-up to house TYK2/JAK1 program
Plus Jazz’s Sativex misses and updates from Sanofi, Spero, SonALAsense and more
BioCentury | Apr 8, 2022
Deals
Werewolf deal gives Jazz first immuno-oncology candidate
Jazz pays $15M up front to in-license rights to Werewolf’s conditionally activated oncology therapeutic
BioCentury | Mar 29, 2022
Regulation
March 28 Quick Takes: Japan approvals include Sanofi’s Xenpozyme for rare disease
Plus more bad news for ALS and Biogen, Eagle acquiring Acacia, and more
BioCentury | Jan 19, 2022
Deals
UCB pads epilepsy portfolio with $1.9B Zogenix takeout
With UCB patent cliff looming, Zogenix takeout comes ahead of possible Fintepla label expansion
BioCentury | Sep 30, 2021
Deals
PAH candidate central to Merck’s $11.5B Acceleron takeout
Pharma views Acceleron’s sotatercept as growth driver following Keytruda patent expiration
BioCentury | Aug 19, 2021
Regulation
Aug. 18 Quick Takes: Jardiance’s label gains heart failure indication
RA leads $50M series B for Jnana, plus a deal for Verily, no deal for CureVac and Marinus data
BioCentury | Aug 3, 2021
Deals
A $3.2B takeout of partner Translate Bio tees Sanofi up to build out mRNA franchise
Year’s second-largest biotech buyout caps nearly 200% stock run sparked by COVID program
Items per page:
1 - 10 of 234